Table 2.
Hazard ratios (HR) for the combination of IGHV mutational status with CK subtypes
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| HR | 95% C.I | p values | HR | 95% C.I | p values | |
| TTFT | ||||||
| M-noCK | 1.00 | – | – | 1.00 | – | – |
| U-CK1 | 4.31 | 3.14–5.90 | <0.0001 | 3.98 | 2.87–5.52 | <0.0001 |
| CK2 | 4.89 | 2.99–7.99 | <0.0001 | 5.12 | 3.5–7.47 | <0.0001 |
| OS | ||||||
| M-noCK | 1.00 | – | – | 1.00 | – | – |
| U-CK1 | 3.10 | 1.81–5.30 | <0.0001 | 3.14 | 1.75–5.64 | 0.0001 |
| CK2 | 7.07 | 3.13–15.08 | <0.0001 | 7.37 | 3.97–13.69 | <0.0001 |
95% C.I. 95% confidential interval, M-noCK mutated IGHV without complex karyotype, U-CK1 unmutated IGHV and/or type 1 complex karyotype, CK2 type 2 complex karyotype, TTFT time to first treatment, OS overall survival